羟保松
中文名称:
羟保松
中文同义词:
羟保松;羟布宗;羟基保泰松;羟基保泰松,坦特利尔,羟保松;羟基保泰松溶液,100PPM
英文名称:
OXYPHENYL BUTAZONE
英文同义词:
LABOTEST-BB LT00134684;OXYPHENYL BUTAZONE;1-(p-Hydroxyphenyl)-2-phenyl-3,5-dioxo-4-N-butylpyrazolidine;1-(p-Hydroxyphenyl)-2-phenyl-4-butyl-3,5-pyrazolidinedione;1-(p-hydroxyphenyl)-2-phenyl-4-butylpyrazolidine-3,5-dione;1-Phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-butylpyrazolidine;1-phenyl-2-(p-hydroxyphenyl)-3,5-dioxo-4-n-butylpyrazolidine;1-p-hydroxyphenyl-2-phenyl-3,5-dioxo-4-n-butylpyrazolidine
CAS号:
129-20-4
分子式:
C19H20N2O3
分子量:
324.37
EINECS号:
204-936-2
相关类别:
抗炎镇痛药物;Active Pharmaceutical Ingredients;Aromatics;Heterocycles;Intermediates Fine Chemicals;Pharmaceuticals
Mol文件:
129-20-4.mol
熔点
109-111°C
沸点
462.71°C (rough estimate)
密度
1.2118 (rough estimate)
折射率
1.6140 (estimate)
储存条件
-20°C
溶解度
DMSO: soluble10mg/mL, clear
酸度系数(pKa)
pKa 4.7/10.0±0.2(H2O,t =25,Iundefined) (Uncertain)
形态
powder
颜色
white to brown
水溶解性
20mg/L(room temperature)
CAS 数据库
129-20-4(CAS DataBase Reference)
(IARC)致癌物分类
3 (Vol. 13, Sup 7) 1987
EPA化学物质信息
3,5-Pyrazolidinedione, 4-butyl-1-(4-hydroxyphenyl)-2-phenyl- (129-20-4)
生物活性
Oxyphenbutazone 是一种苯丁酮衍生物，具有抗炎作用。Oxyphenbutazone 是一种非选择性的 COX 抑制剂。Oxyphenbutazone 能选择性地杀死不复制的结核分枝杆菌。
靶点
COX
体外研究
Oxyphenbutazone enhances the anticancer efficiency of methotrexate (MTX) in Hep3B cells.
Oxyphenbutazone (2.5 -7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells.
Oxyphenbutazone exhibits reparative effects in the hepatocytes.
Cell Cytotoxicity Assay
Cell Line: Hep3B cells
Concentration: 2.5 µM, 5 µM, 7.5 µM
Incubation Time: 48 hours
Result: Enhanced the cytotoxicity of MTX.
Cell Line:
Hep3B cells
Concentration:
2.5 µM, 5 µM, 7.5 µM
Incubation Time:
48 hours
Result:
Enhanced the cytotoxicity of MTX.
体内研究
Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.).
Animal Model: 5–6 weeks Wistar strain albino male rats (150–220 g)
Dosage: 70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week)
Administration: Oral administration; once a week; in two divided doses; for 13 weeks
Result: Exerted potential anticancer activity in rats when co-treatment with MTX.
Animal Model:
5–6 weeks Wistar strain albino male rats (150–220 g)
Dosage:
70 mg/kg/week (co-treatment with MTX 5.0 or 2.5 mg/kg/week)
Administration:
Oral administration; once a week; in two divided doses; for 13 weeks
Result:
Exerted potential anticancer activity in rats when co-treatment with MTX.
化学性质
白色结晶或结晶性粉末。熔点124-125℃。易溶于乙醇、丙酮，溶于氯仿、苯、醚，不溶于水。易溶于氢氧化碳或碳酸碱溶液。无臭，味苦。
用途
用于治疗痛风、关节炎、风湿性或类风湿性关节炎及关节强硬性脊椎炎等。
危险品标志
Xn,N
危险类别码
22-50
安全说明
61
危险品运输编号
UN 3077 9 / PGIII
WGK Germany
3
